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Introduction
The term CAPS (Cryopyrin-Associated Periodic Syn-
dromes) identifies a spectrum of autoinflammatory
diseases caused by heterozygous mutations of the
CIAS1/NLRP3. Affected individuals may present three
different phenotypes: Familial Cold Autoinflammatory
Syndrome (FCAS), Muckle-Wells Syndrome (MWS)
and CINCA syndrome, the most severe form of the
clinical spectrum. Clinical manifestations include
urticaria-like rash, recurrent fever, arthralgia, conjunc-
tivitis; chronic aseptic meningitis, cerebral atrophy and
bone malformations in the severe cases.
The term CAPS (Cryopyrin-Associated Periodic
Syndromes) identifies a spectrum of autoinflammatory
diseases caused by heterozygous mutations of the
CIAS1/NLRP3. Affected individuals may present three
different phenotypes: Familial Cold Autoinflammatory
Syndrome (FCAS), Muckle-Wells Syndrome (MWS) and
CINCA syndrome, the most severe form of the clinical
spectrum. Clinical manifestations include urticaria-like
rash, recurrent fever, arthralgia, conjunctivitis; chronic
aseptic meningitis, cerebral atrophy and bone malforma-
tions in the severe cases.
Objectives
To describe the long-term clinical course of a cohort of
patients carrying two different low-penetrance NLRP3
mutations (V198M and Q703K).
Methods
Six patients were identified carrying the NLRP3 V198M
mutation (mean age 10,35 ± 4,73 years, 4 males and 2
females), and 5 patients were identified carrying the
NLRP3 Q703K (mean age 9,72 ± 4,55 years, 3 males
and 2 females). All were Caucasians.
Results
In the V198M cohort the mean age at disease onset was
5,85 ± 4,08 years. All patients had symptoms consistent
with recurrent inflammatory syndrome: 6/6 presented
recurrent episodes of skin lesions and arthralgia, 4/6 of
fever attacks, 3/6 of arthritis, 2/6 of headache and subcuta-
neous edema. One patient showed fatigue, conjunctivitis
and recurrent abdominal pain. Half of the patients had a
positive family history for recurrent inflammatory epi-
sodes. In 3 out of 6 patients the severity of phenotype and
the persistence of elevated acute phase reactants, led to
initiation of anti IL-1 therapy with immediate benefit. In
the cohort of patients with Q703K variant the mean age at
disease onset was 3,73 ± 3,33 years. All patients had skin
rash, 4/5 patients presented recurrent fever, 3/5 arthralgia
and myalgia, 2/5 subcutaneous edema, pharyngitis and
lymphadenitis; 1 out of 5 patients had mild arthritis, head-
ache and abdominal pain. Only in 1 case, symptoms were
triggered or worsened by cold exposure. None of our
patients had a family history relevant for autoinflammatory
symptoms. Laboratory test showed no increase in acute
phase reactants, with one exception. This patient pre-
sented also with recurrent fevers, treatment resistant epi-
lepsy and carries an heterozygous MEFV mutation. She
failed colchicine and anti IL-1 therapy was started with
benefit.
Conclusion
The pathogenic significance of these NLRP3 mutations is
still discussed. In our experience patients carrying Q703K
mutation appear to have a milder and self-limited pheno-
type than those with V198M variant in which therapy
with IL-1 inhibitor drugs is often necessary. The factors
that affect the pathogenic consequences of these variants
are still to be established.
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